.Pharmacolibrary.Drugs.ATC.J.J01AA15_1

Information

Omadacycline is a modern aminomethylcycline antibiotic, structurally related to tetracyclines, used for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. It is approved for clinical use and is active against a broad spectrum of Gram-positive and some Gram-negative bacteria.

Pharmacokinetics

Healthy adult subjects, both sexes, 18–65 years, following single and multiple intravenous doses.

References

1. Yang, H, et al., & Wu, X (2022). Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects. Frontiers in pharmacology 13 869237–None. DOI:10.3389/fphar.2022.869237 PUBMED:https://pubmed.ncbi.nlm.nih.gov/35529438

2. Rodvold, KA, et al., & Pai, MP (2020). Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. Clinical pharmacokinetics 59(4) 409–425. DOI:10.1007/s40262-019-00843-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31773505

3. Sanders, M, et al., & Beringer, P (2024). Pharmacokinetics of Omadacycline in Adults with Cystic Fibrosis. Clinical pharmacokinetics 63(12) 1701–1709. DOI:10.1007/s40262-024-01440-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/39581957

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)